Interstitial Cystitis Market

The DelveInsight’s Interstitial Cystitis Market Insights Report offers a thorough comprehension of the Interstitial Cystitis, historical and forecasted epidemiology, and Interstitial Cystitis market patterns in the 7MM (United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan).

Some of the Key Highlights from Interstitial Cystitis Market Report

• In 2018, the total diagnosed prevalent population of IC patients in the seven major markets was found to be more than 2,000,000.

• The severity of IC can be classified into three categories: mild, moderate, and severe.

• KRP-116D (Kyorin Pharmaceutical), Certolizumab pegol (Cimzia) (UCB Pharma), LP-08 (Lipella Pharmaceuticals), ASP6294 (Astellas Pharma), SI-722 (Seikagaku Corporation), and others are some of the emerging therapies in the Interstitial Cystitis market.

• Key players in the Interstitial Cystitis market include Kyorin Pharmaceutical, UCB Pharma, Lipella Pharmaceuticals, Astellas Pharma, Seikagaku Corporation, among others.

For more information request sample @ Interstitial Cystitis Market Insights

Interstitial Cystitis market report covers current clinical strategies, new drugs, Interstitial Cystitis market share of individual therapies, and current and forecasted Interstitial Cystitis market size from 2018 to 2030 segmented by seven major markets. The report also examines existing Interstitial Cystitis treatment practices/algorithms, market dynamics, market challenges, and unmet patient needs in order to identify and evaluate the market’s underlying potential.

Interstitial Cystitis: Disease Overview

Interstitial Cystitis (IC), also known as Painful Bladder Syndrome, is a recurrent disease that causes pressure in the bladder, discomfort in the bladder, and occasionally pelvic pain. The pain varies in intensity from moderate to intense. The bladder is a hollow, muscular organ that stores urine and expands until it is complete, at which point it sends signals to the brain through the pelvic nerves that it is time to urinate, causing most people to feel the urge to urinate.

Interstitial Cystitis Epidemiology Segmentation

• Interstitial Cystitis Total Prevalent Population

• Interstitial Cystitis Gender-Specific Prevalent Population

• Interstitial Cystitis Total Diagnosed Prevalent Population

• Interstitial Cystitis Severity-Based Diagnosed Prevalent Population

• Interstitial Cystitis Type-Specific Diagnosed Prevalent Population

• Interstitial Cystitis Age-Specific Diagnosed Prevalent Population

Interstitial Cystitis Treatment Landscape

Since the etiology and pathogenesis of IC are unknown, and there is no cure, the purpose of care is to alleviate symptoms and improve the patients’ quality of life. The FDA approved drugs used for treating patients with IC include Elmiron (Janssen Pharmaceutical).

Some major treatment options for Interstitial Cystitis are:

• Surgical Interventions

• Diet Management and Physical Therapy

• Transcutaneous Electrical Nerve Stimulation (TENS)

• Antidepressants (TCAs, SSRIS and SNRIS)

• Immunosuppressive Drugs (Cyclosporine)

• Bladder Instillations (Alkalinized Lidocaine and Heparin,  DMSO and Sodium Hyaluronate)

Interstitial Cystitis Market

• In 2018, the market size of IC in the seven major markets was estimated to be USD 1,655 million, with growth expected over the study period (2018–2030).

• Germany had the largest market size in 2018, among the EU5 countries, while Spain had the smallest market size in 2018.

For more insights visit, Interstitial Cystitis Market Landscape

Interstitial Cystitis Pipeline Therapies and Major Players

• KRP-116D: Kyorin Pharmaceutical

• Certolizumab pegol (Cimzia): UCB Pharma

• LP-08: Lipella Pharmaceuticals

• ASP6294: Astellas Pharma

• SI-722: Seikagaku Corporation

Interstitial Cystitis Market Drivers

• FDA approved Oral medication

• Increasing emerging therapies

• Increasing awareness

Interstitial Cystitis Market Barriers

• Lack of Consensus Definition

• Intermittent Pipeline Activity

• Absence of Validated Biomarkers

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

Interstitial Cystitis Key Companies: Kyorin Pharmaceutical, UCB Pharma, Lipella Pharmaceuticals, Astellas Pharma, Seikagaku Corporation, among others. 

Interstitial Cystitis Key Pipeline Therapies: KRP-116D (Kyorin Pharmaceutical), Certolizumab pegol (Cimzia) (UCB Pharma), LP-08 (Lipella Pharmaceuticals), ASP6294 (Astellas Pharma), SI-722 (Seikagaku Corporation), and others.

Interstitial Cystitis Market Segmentation: By Geography, By Interstitial Cystitis therapies

Analysis: Comparative and conjoint analysis of Interstitial Cystitis emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents 

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Interspinous Spacers Market

Get comprehensive historical and forecast analysis of Interspinous Spacers Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Medtronic, NuVasive, Inc., Paradigm Spine (RTI Surgical), Zimmer Biomet, Vertiflex, Inc., Life Spine, Inc., and Globus Medical, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/